151 related articles for article (PubMed ID: 38112841)
1. Parental History of Type 2 Diabetes Mellitus and PNPLA3 Polymorphism Increase the Risk of Severe Stages of Nonalcoholic Fatty Liver Disease.
Wajsbrot NB; Leite NC; Franca PHC; Cardoso CRL; Salles GF; Villela-Nogueira CA
Dig Dis Sci; 2024 Feb; 69(2):634-642. PubMed ID: 38112841
[TBL] [Abstract][Full Text] [Related]
2. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study.
Krawczyk M; Rau M; Schattenberg JM; Bantel H; Pathil A; Demir M; Kluwe J; Boettler T; Lammert F; Geier A;
J Lipid Res; 2017 Jan; 58(1):247-255. PubMed ID: 27836992
[TBL] [Abstract][Full Text] [Related]
3. PNPLA3 gene polymorphism in Brazilian patients with type 2 diabetes: A prognostic marker beyond liver disease?
Machado CM; Leite NC; França PH; Cardoso CR; Salles GF; Villela-Nogueira CA
Nutr Metab Cardiovasc Dis; 2019 Sep; 29(9):965-971. PubMed ID: 31377187
[TBL] [Abstract][Full Text] [Related]
4. Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population.
Mazo DF; Malta FM; Stefano JT; Salles APM; Gomes-Gouvea MS; Nastri ACS; Almeida JR; Pinho JRR; Carrilho FJ; Oliveira CP
Ann Hepatol; 2019; 18(3):466-471. PubMed ID: 31054980
[TBL] [Abstract][Full Text] [Related]
5. The role of PNPLA3 and TM6SF2 polymorphisms on liver fibrosis and metabolic abnormalities in Brazilian patients with chronic hepatitis C.
Oliveira AIN; Malta FM; Zitelli PMY; Salles APM; Gomes-Gouvea MS; Nastri ACS; Pinho JRR; Carrilho FJ; Oliveira CP; Mendes-Corrêa MC; Pessoa MG; Mazo DF
BMC Gastroenterol; 2021 Feb; 21(1):81. PubMed ID: 33622266
[TBL] [Abstract][Full Text] [Related]
6.
Lisboa QC; Nardelli MJ; Pereira PA; Miranda DM; Ribeiro SN; Costa RSN; Versiani CA; Vidigal PVT; Ferrari TCA; Couto CA
World J Hepatol; 2020 Oct; 12(10):792-806. PubMed ID: 33200017
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the association of a variant in PNPLA3 and TM6SF2 with fibrosis progression in patients with chronic hepatitis C infection after eradication: A retrospective study.
Kang Q; Xu J; Luo H; Tan N; Chen H; Cheng R; Pan J; Han Y; Yang Y; Liu D; Xi H; Yu M; Xu X
Gene; 2022 Apr; 820():146235. PubMed ID: 35143946
[TBL] [Abstract][Full Text] [Related]
8. Reduction of Caloric Intake Might Override the Prosteatotic Effects of the PNPLA3 p.I148M and TM6SF2 p.E167K Variants in Patients with Fatty Liver: Ultrasound-Based Prospective Study.
Krawczyk M; Stachowska E; Milkiewicz P; Lammert F; Milkiewicz M
Digestion; 2016; 93(2):139-48. PubMed ID: 26745555
[TBL] [Abstract][Full Text] [Related]
9. Correlations between PNPLA3 Gene Polymorphisms and NAFLD in Type 2 Diabetic Patients.
Gavril OI; Arhire LI; Gavril RS; Zota MI; Gherasim A; Nita O; Drugescu A; Oprescu AC; Esanu IM; Mitu F; Graur M; Mihalache L
Medicina (Kaunas); 2021 Nov; 57(11):. PubMed ID: 34833467
[No Abstract] [Full Text] [Related]
10. Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population.
Petta S; Di Marco V; Pipitone RM; Grimaudo S; Buscemi C; Craxì A; Buscemi S
Liver Int; 2018 Nov; 38(11):2060-2068. PubMed ID: 29577560
[TBL] [Abstract][Full Text] [Related]
11. Examining genetic associations with hepatic steatosis in Mexican-origin adults.
Trejo MJ; Morrill KE; Klimentidis YC; Garcia DO
Ann Hepatol; 2023; 28(5):101120. PubMed ID: 37271481
[TBL] [Abstract][Full Text] [Related]
12. Genetic Variants in nicotinamide-N-methyltransferase (NNMT) gene are related to the stage of non-alcoholic fatty liver disease diagnosed by controlled attenuation parameter (CAP)-fibroscan.
Hasan EM; Abd Al Aziz RA; Sabry D; Darweesh SK; Badary HA; Elsharkawy A; Abouelkhair MM; Yosry A
J Gastrointestin Liver Dis; 2018 Sep; 27(3):265-272. PubMed ID: 30240470
[TBL] [Abstract][Full Text] [Related]
13. Psoriasis and steatotic liver disease: Are PNPLA3 and TM6SF2 polymorphisms suitable for the hepato-dermal axis hypothesis?
Agoglia L; Cardoso AC; Barbosa L; Victer CSXL; Carneiro S; de França PHC; Chindamo MC; Villela-Nogueira CA
Ann Hepatol; 2024 Feb; 29(4):101477. PubMed ID: 38360269
[TBL] [Abstract][Full Text] [Related]
14. Non-Alcoholic Fatty Liver Disease in Long-Term Type 2 Diabetes: Role of rs738409
Mana MF; Parisi MCR; Correa-Giannella ML; Neto AM; Yamanaka A; Cunha-Silva M; Cavaleiro AM; Dos Santos CR; Pavan CR; Sevá-Pereira T; Dertkigil SSJ; Mazo DF
Molecules; 2022 May; 27(10):. PubMed ID: 35630668
[TBL] [Abstract][Full Text] [Related]
15. APOC3 rs2070666 Is Associated with the Hepatic Steatosis Independently of PNPLA3 rs738409 in Chinese Han Patients with Nonalcoholic Fatty Liver Diseases.
Zhang RN; Zheng RD; Mi YQ; Zhou D; Shen F; Chen GY; Zhu CY; Pan Q; Fan JG
Dig Dis Sci; 2016 Aug; 61(8):2284-2293. PubMed ID: 27059980
[TBL] [Abstract][Full Text] [Related]
16. Noninvasive characterization of graft steatosis after liver transplantation.
Karlas T; Kollmeier J; Böhm S; Müller J; Kovacs P; Tröltzsch M; Weimann A; Bartels M; Rosendahl J; Mössner J; Berg T; Keim V; Wiegand J
Scand J Gastroenterol; 2015 Feb; 50(2):224-32. PubMed ID: 25429378
[TBL] [Abstract][Full Text] [Related]
17. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
[TBL] [Abstract][Full Text] [Related]
18. Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease.
Paternostro R; Staufer K; Traussnigg S; Stättermayer AF; Halilbasic E; Keritam O; Meyer EL; Stift J; Wrba F; Sipos B; Canbay A; Schlattjan M; Aigner E; Datz C; Stickel F; Schafmayer C; Hampe J; Buch S; Prager G; Munda P; Mandorfer M; Ferenci P; Trauner M
Hepatol Int; 2021 Aug; 15(4):922-933. PubMed ID: 34076851
[TBL] [Abstract][Full Text] [Related]
19. Different effects of low muscle mass on the risk of non-alcoholic fatty liver disease and hepatic fibrosis in a prospective cohort.
Choe HJ; Lee H; Lee D; Kwak SH; Koo BK
J Cachexia Sarcopenia Muscle; 2023 Feb; 14(1):260-269. PubMed ID: 36403577
[TBL] [Abstract][Full Text] [Related]
20. Effects of PNPLA3, TM6SF2 and SAMM50 on the development and severity of non-alcoholic fatty liver disease in children.
Lee KJ; Moon JS; Kim NY; Ko JS
Pediatr Obes; 2022 Feb; 17(2):e12852. PubMed ID: 34490745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
